Approved & therapeutic
Vancomycin
Vancocin
Vancomycin is a glycopeptide antibiotic and a mainstay of treatment for serious Gram-positive infection, including methicillin-resistant Staphylococcus aureus. It has been in clinical use since 1958.
Also known as: Firvanq, vanc
- Status
- Vancomycin is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Approximately 4 to 6 hours in normal renal function, markedly prolonged in renal impairment.
- How it's taken
- Intravenous infusion; oral capsules for Clostridioides difficile colitis
- Mechanism
- Immune modulation
How Vancomycin works
Vancomycin binds the D-alanyl-D-alanine terminus of peptidoglycan precursors in the Gram-positive cell wall, physically blocking the transpeptidation and transglycosylation steps of cell wall synthesis. Because it binds the substrate rather than an enzyme, resistance requires the organism to remodel its cell wall precursors — which is why resistance emerged slowly, and why the VanA mechanism substitutes D-alanyl-D-lactate.
What research has looked at
- Reliable activity against MRSA and most Gram-positive pathogens, with decades of clinical experience.
- Oral vancomycin is not absorbed and is therefore the treatment of choice for Clostridioides difficile colitis, acting entirely within the gut lumen.
- Resistance in Staphylococcus aureus remains rare, though enterococcal resistance is well established.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Nephrotoxicity, particularly with higher exposures and with concurrent piperacillin-tazobactam or other nephrotoxins. Therapeutic drug monitoring is required, and AUC-guided dosing has largely replaced trough-only monitoring.
- Vancomycin infusion reaction — flushing of the upper body from direct mast cell degranulation, historically called "red man syndrome". It is an infusion-rate phenomenon, not an allergy, and is managed by slowing the infusion.
- Ototoxicity, less common than with aminoglycosides but reported.
- Neutropenia and thrombocytopenia with prolonged courses.
- It penetrates poorly into lung and central nervous system tissue, which limits its effectiveness in some serious infections despite in vitro susceptibility.
Sources
- FDA approved-drug listing for vancomycin · U.S. Food & Drug Administration
- DailyMed prescribing information for vancomycin · NIH · DailyMed
- PubMed research on vancomycin AUC dosing nephrotoxicity · NIH · National Library of Medicine
- DrugBank record for vancomycin · DrugBank
Track Vancomycin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Vancomycin FAQ
What is Vancomycin?
Vancomycin is a glycopeptide antibiotic and a mainstay of treatment for serious Gram-positive infection, including methicillin-resistant Staphylococcus aureus. It has been in clinical use since 1958.
How does Vancomycin work?
Vancomycin binds the D-alanyl-D-alanine terminus of peptidoglycan precursors in the Gram-positive cell wall, physically blocking the transpeptidation and transglycosylation steps of cell wall synthesis. Because it binds the substrate rather than an enzyme, resistance requires the organism to remodel its cell wall precursors — which is why resistance emerged slowly, and why the VanA mechanism substitutes D-alanyl-D-lactate.
Is Vancomycin FDA approved?
Yes. Vancomycin is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Vancomycin?
Reported half-life: Approximately 4 to 6 hours in normal renal function, markedly prolonged in renal impairment.
How is Vancomycin taken?
Intravenous infusion; oral capsules for Clostridioides difficile colitis.
What side effects have been reported with Vancomycin?
Reported in the sources: Nephrotoxicity, particularly with higher exposures and with concurrent piperacillin-tazobactam or other nephrotoxins. Therapeutic drug monitoring is required, and AUC-guided dosing has largely replaced trough-only monitoring; Vancomycin infusion reaction — flushing of the upper body from direct mast cell degranulation, historically called "red man syndrome". It is an infusion-rate phenomenon, not an allergy, and is managed by slowing the infusion; Ototoxicity, less common than with aminoglycosides but reported; Neutropenia and thrombocytopenia with prolonged courses; It penetrates poorly into lung and central nervous system tissue, which limits its effectiveness in some serious infections despite in vitro susceptibility.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.